Dipraglurant + Placebo
Phase 2/3Terminated 0 watching 0 views this week⚡ Active
57
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Parkinson Disease
Conditions
Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Trial Timeline
Aug 6, 2021 → Aug 15, 2022
NCT ID
NCT04857359About Dipraglurant + Placebo
Dipraglurant + Placebo is a phase 2/3 stage product being developed by Addex Therapeutics for Parkinson Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT04857359. Target conditions include Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias.
Hype Score Breakdown
Clinical
22
Activity
15
Company
2
Novelty
7
Community
8
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05027997 | Phase 2 | Completed |
| NCT04857359 | Phase 2/3 | Terminated |
Competing Products
20 competing products in Parkinson Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| UB-312 + Placebo | Vaxxinity | Phase 1 | 25 |
| NAV5001 + DaTscan | Navidea Biopharmaceuticals | Phase 3 | 69 |
| exidavnemab + Placebo Comparator | BioArctic AB | Phase 2 | 49 |
| LY4006896 + Placebo | Eli Lilly | Phase 1 | 33 |
| ATH-1017 + Placebo | LeonaBio | Phase 2 | 44 |
| piclozotan + 0.9% sodium chloride (normal saline) | Daiichi Sankyo | Phase 2 | 52 |
| Mirabegron + Placebo | Astellas Pharma | Approved | 85 |
| E2007 | Eisai | Phase 3 | 77 |
| ARICEPT | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Phase 3 | 77 |
| GPI 1485 | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 3 | 77 |
| Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior Placebo | Eisai | Phase 3 | 77 |
| Equfina 50 mg | Eisai | Pre-clinical | 23 |
| Equfina | Eisai | Pre-clinical | 23 |
| perampanel + placebo | Eisai | Phase 2 | 52 |
| Lemborexant + placebo | Eisai | Approved | 85 |
| Placebo + E2007 + E2007 | Eisai | Phase 3 | 77 |
| Safinamide Mesilate | Eisai | Approved | 85 |
| E2007 + E2007 + E2007 | Eisai | Phase 2 | 52 |